Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to :
- Determine how effective cisplatin or carboplatin is in slowing the time it takes for ER
negative (estrogen-receptor-negative), PR negative (progesterone receptor-negative),
HER2 negative (human epidermal growth factor receptor 2) breast cancer to progress.
Cisplatin and carboplatin are anti-cancer chemotherapy drugs that stop cancer cells from
growing abnormally and is used to treat other cancers.
- Evaluate a new biomarker to help determine which breast cancers are most likely to
respond to cisplatin chemotherapy
The hypothesis is that Triple Negative metastatic breast cancer may be particularly sensitive
to platinum, and that a subgroup of those patients may have a marker in their tumors that
predicts response.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Beth Israel Deaconess Medical Center Dana-Farber Cancer Institute North Shore Medical Center